AGP Executive Report
Last update: 2 hours agoBiotech Spotlight: Hansa Biopharma has just landed a late-breaking, oral ATC 2026 slot for its ConfIdeS Phase 3 kidney-transplant trial, with 12-month results slated for Boston (June 22) and a focus on eGFR in highly sensitized patients. Education & Community: Princeton’s Class Day honored student leaders and service, spotlighting campus impact beyond the classroom. Diplomacy Watch: Modi’s Nordic push—framed as a green strategic partnership—keeps rolling, with talks covering clean energy, digitalisation, AI, and research as India deepens ties with Norway, Sweden, Finland, Iceland, and Denmark. Regulation & Health: In Europe, Merck’s KEYTRUDA plus Padcev gained a positive CHMP opinion for a cisplatin-ineligible bladder-cancer setting, while Pharming’s Joenja (leniolisib) secured EU marketing authorization as the first APDS treatment. Arts & Culture: Uruguay donated a major sculpture to the ICC in The Hague, adding a fresh art-and-justice moment to the week.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
